Sharmilee Gnanapavan

4.2k total citations · 3 hit papers
71 papers, 2.6k citations indexed

About

Sharmilee Gnanapavan is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Sharmilee Gnanapavan has authored 71 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pathology and Forensic Medicine, 23 papers in Neurology and 11 papers in Rheumatology. Recurrent topics in Sharmilee Gnanapavan's work include Multiple Sclerosis Research Studies (39 papers), Peripheral Neuropathies and Disorders (10 papers) and Polyomavirus and related diseases (10 papers). Sharmilee Gnanapavan is often cited by papers focused on Multiple Sclerosis Research Studies (39 papers), Peripheral Neuropathies and Disorders (10 papers) and Polyomavirus and related diseases (10 papers). Sharmilee Gnanapavan collaborates with scholars based in United Kingdom, United States and Netherlands. Sharmilee Gnanapavan's co-authors include Gavin Giovannoni, Stephen A. Bustin, Márta Korbonits, R Carpenter, Ashley Grossman, Damian Morris, Peter D. Fairclough, Patrick McGee, Satya Bhattacharya and Blerina Kola and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Neurology.

In The Last Decade

Sharmilee Gnanapavan

67 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans

2002 1.1k citations Sharmilee Gnanapavan et al. profile →
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

2015 275 citations Gavin Giovannoni, Benjamin Turner et al. Multiple Sclerosis and Related Disorders profile →
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management

2024 65 citations Sharmilee Gnanapavan, Jens Kühle et al. EBioMedicine profile →

Peers

Countries citing papers authored by Sharmilee Gnanapavan

Since Specialization

Citations

This map shows the geographic impact of Sharmilee Gnanapavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharmilee Gnanapavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharmilee Gnanapavan more than expected).

Fields of papers citing papers by Sharmilee Gnanapavan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharmilee Gnanapavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharmilee Gnanapavan. The network helps show where Sharmilee Gnanapavan may publish in the future.

Co-authorship network of co-authors of Sharmilee Gnanapavan

This figure shows the co-authorship network connecting the top 25 collaborators of Sharmilee Gnanapavan. A scholar is included among the top collaborators of Sharmilee Gnanapavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharmilee Gnanapavan. Sharmilee Gnanapavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosis 2025 ·Multiple Sclerosis and Related Disorders ·(unknown), Anisha Doshi, Sharmilee Gnanapavan	0
2	Self-reported cognitive dysfunction and memory impairment in Systemic Autoimmune Rheumatic Diseases (SARDs): a mixed methods analysis of the INSPIRE cohort 2025 ·Lara D. Veeken ·(unknown), Thomas Pollak, (unknown), Efthalia Massou, Felix Naughton, James A. Bourgeois, (unknown), Guy Leschziner, Alessandra Bortoluzzi, (unknown), (unknown), Martha Piper, Laura Andréoli, Xiaowei Yan, Sharmilee Gnanapavan, Arvind Kaul, David D’Cruz, Melanie Sloan	1
3	Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis 2025 ·EBioMedicine ·Florian Deisenhammer, Harald Hegen, Georgina Arrambide, Brenda Banwell, (unknown), Sharmilee Gnanapavan, Xavier Montalbán, Hayrettin Tumani, Maria Alice V. Willrich, Mark S. Freedman	3
4	Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells 2024 ·Clinical Immunology ·Francesca Ammoscato, (unknown), (unknown), Jonathan P. Bestwick, (unknown), Michael Andrews, (unknown), David W. Holden, Ashok Adams, Lucia Bianchi, Ben Turner, Mónica Marta, Klaus Schmierer, David Baker, Gavin Giovannoni, Sharmilee Gnanapavan	4
5	Effects of cladribine on intrathecal and peripheral B and plasma cells 2024 ·Clinical & Experimental Immunology ·(unknown), Sophie Stephenson, Gina M. Doody, Amy MacDougall, (unknown), Francesca Ammoscato, Michael Andrews, Sharmilee Gnanapavan, Gavin Giovannoni, Sofia Grigoriadou, (unknown), David W. Holden, (unknown), (unknown), (unknown), David Baker, Reuben Tooze, Klaus Schmierer	0
6	Anaesthetic management of people with multiple sclerosis 2023 ·Multiple Sclerosis and Related Disorders ·Nicolas Dubuisson, (unknown), Mónica Marta, Sharmilee Gnanapavan, Benjamin Turner, David Baker, Klaus Schmierer, Gavin Giovannoni, (unknown), (unknown)	2
7	Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? (P9-4.002) 2022 ·Neurology ·(unknown), Mónica Marta, Sharmilee Gnanapavan, David Baker, Klaus Schmierer	2
8	Protecting people with multiple sclerosis through vaccination 2020 ·Practical Neurology ·Saúl Reyes, Mary Ramsay, Shamez Ladhani, Gayatri Amirthalingam, Neena Singh, (unknown), Joela Mathews, Jonathan Lambourne, Mónica Marta, Benjamin Turner, Sharmilee Gnanapavan, Ruth Dobson, Klaus Schmierer, Gavin Giovannoni	36
9	GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains 2020 ·Scientific Reports ·Gauri Saxena, (unknown), (unknown), Meleri Jones, Sharmilee Gnanapavan, Gavin Giovannoni, Klaus Schmierer, James A. Garnett, David Baker, Angray S. Kang	5
10	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Saúl Reyes, Sebastián Suárez, (unknown), Özlem Kayım Yıldız, Joela Mathews, (unknown), F.Kathryn Edwards, (unknown), Benjamin Turner, Mónica Marta, Sharmilee Gnanapavan, Klaus Schmierer, Gavin Giovannoni	6
11	NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment (P4.2-008) 2019 ·Neurology ·(unknown), Francesca Ammoscato, Jonathan Ciron, Florence Bucciarelli, (unknown), Damien Biotti, (unknown), (unknown), (unknown), (unknown), Fabrice Bonneville, Sharmilee Gnanapavan, David Brassat	1
12	Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine 2018 ·Multiple Sclerosis and Related Disorders ·Özlem Kayım Yıldız, (unknown), (unknown), Nicolas Dubuisson, (unknown), Gavin Giovannoni, Andrea Malaspina, David Baker, Sharmilee Gnanapavan, Klaus Schmierer	14
13	Treating multiple sclerosis with generic cladribine 2017 ·Queen Mary Research Online (Queen Mary University of London) ·César Álvarez-González, (unknown), Joela Mathews, (unknown), (unknown), Sharmilee Gnanapavan, Mónica Marta, Gavin Giovannoni, David Baker, Klaus Schmierer	1
14	Association of Serum Neurofilament Light Chain with Cognitive and Disability Measures in Patients with Very Early MS: A Longitudinal Study (P1.396) 2016 ·Neurology ·Bardia Nourbakhsh, Sharmilee Gnanapavan, Gavin Giovannoni, Laura Julián, Rebecca Spain, Jens Kühle, Emmanuelle Waubant	1
15	Is it time to target no evident disease activity (NEDA) in multiple sclerosis? breakdown → 2015 ·Multiple Sclerosis and Related Disorders ·Gavin Giovannoni, Benjamin Turner, Sharmilee Gnanapavan, Curtis Offiah, Klaus Schmierer, Mónica Marta	275
16	Growth associated protein (GAP-43): Cloning and the development of a sensitive ELISA for neurological disorders 2014 ·Journal of Neuroimmunology ·Sharmilee Gnanapavan, Nasim Yousaf, Wendy Heywood, Donna Grant, Kevin Mills, Yuti Chernajovsky, Geoff Keir, Gavin Giovannoni	7
17	A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome 2014 ·BMC Neurology ·Sharmilee Gnanapavan, Zane Jaunmuktane, (unknown), (unknown), Klaus Schmierer	6
18	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression 2013 ·PLoS ONE ·Sharmilee Gnanapavan, Donna Grant, S. V. Morant, J Furby, Tom Hayton, Charlotte E. Teunissen, Valerio Leoni, Mónica Marta, Robert Brenner, Jacqueline Palace, David H. Miller, Raj Kapoor, Gavin Giovannoni	42
19	Parinaud's syndrome – A rare presentation of clinically isolated syndrome 2013 ·Multiple Sclerosis and Related Disorders ·Sharmilee Gnanapavan, (unknown), James Acheson, Ahmed Toosy	3
20	Early-Onset Cataracts, Spastic Paraparesis, and Ataxia Caused by a Novel Mitochondrial tRNA^Glu(MT-TE) Gene Mutation Causing Severe Complex I Deficiency: A Clinical, Molecular, and Neuropathologic Study 2013 ·Journal of Neuropathology & Experimental Neurology ·Nichola Z. Lax, Sharmilee Gnanapavan, (unknown), Charlotte L. Alston, Langping He, Tuomo Polvikoski, Evelyn Jaros, Dominic G. O’Donovan, John W. Yarham, Douglass M. Turnbull, Andrew Dean, Robert W. Taylor	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact